Evidence map›Paper›PMID 37604954›Full record

ArticleScientific reports2023

Cerebral small vessel disease burden is associated with decreased abundance of gut Barnesiella intestinihominis bacterium in the Framingham Heart Study.

Bernard Fongang, Claudia Satizabal, Tiffany F Kautz, Yannick N Wadop, Jazmyn A S Muhammad, Erin Vasquez, Julia Mathews, Monica Gireud-Goss, Amy R Saklad, Jayandra Himali and 8 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Observational
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Bernard FongangGlenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. fongang@uthscsa.edu.
Claudia SatizabalGlenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Tiffany F KautzGlenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Yannick N WadopGlenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Jazmyn A S MuhammadGlenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Erin VasquezGlenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Julia MathewsGlenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Monica Gireud-GossGlenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Amy R SakladGlenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Jayandra HimaliGlenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Alexa BeiserFramingham Heart Study, Framingham, MA, USA.
Jose E CavazosGlenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Michael C MahaneyDepartment of Human Genetics, South Texas Diabetes and Obesity Institute, The University of Texas Rio Grande Valley School of Medicine, Brownsville, TX, USA.
Gladys MaestreDepartment of Neurosciences and Department of Human Genetics, University of Texas Rio Grande Valley School of Medicine, Brownsville, TX, USA.
Charles DeCarliDepartment of Neurology, Alzheimer's Disease Center, University of California, Davis, Sacramento, CA, USA.
Eric L ShippGlenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Ramachandran S VasanFramingham Heart Study, Framingham, MA, USA.
Sudha SeshadriGlenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
The University of Texas Health Science Center at San Antonio · USThe University of Texas Rio Grande Valley · USBoston Medical Center · USBoston University · USUniversity of California, Davis · US

Funding

UC Davis Alzheimer's Disease Research CenterP30AG072972 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LEE-WAY JIN · 2021 to 2026
$25.2M
South Texas Alzheimer's Disease Research CenterP30AG066546 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Sudha Seshadri · 2021 to 2026
$24.0M
Cognitively Healthy Nonagenarians in the Cross Cohort Collaboration (CCC)RF1AG059421 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI SESHADRI, SUDHA · 2018 to 2018
$6.1M
Rio Grande Valley Alzheimer's Resource Center for Minority Aging Research: Partnerships for ProgressP30AG059305 · NIA · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI Gladys E. Maestre · 2018 to 2026
$5.8M
Multiethnic Validation of VCID biomarkers in South TexasUF1NS125513 · NINDS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI FORNAGE, MYRIAM, SATIZABAL, CLAUDIA L · 2021 to 2021
$2.4M
Sulfatide deficiency: A novel mechanism leading to reactive astrogliosis in aging and Alzheimer’s diseaseRF1AG061729 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HAN, XIANLIN · 2021 to 2021
$1.9M
ADSP Follow-up in Multi-Ethnic Cohorts via Endophenotypes, Omics & Model SystemsU01AG052409 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI FORNAGE, MYRIAM, SESHADRI, SUDHA · 2016 to 2020
$1.6M
Delineating the role of the gut microbiota and its derived metabolites in the development of dementia in multi-ethnic populationsK01NS126489 · NINDS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Bernard Fongang · 2023 to 2026
$882k
NIA NIH HHS P30 AG059305NIA NIH HHS P30 AG066546NIA NIH HHS P30 AG072972NIA NIH HHS RF1 AG059421NIA NIH HHS RF1 AG061729NIA NIH HHS U01 AG052409NINDS NIH HHS K01 NS126489NINDS NIH HHS UF1 NS125513
6 · The paper itself

Abstract

A bidirectional communication exists between the brain and the gut, in which the gut microbiota influences cognitive function and vice-versa. Gut dysbiosis has been linked to several diseases, including Alzheimer's disease and related dementias (ADRD). However, the relationship between gut dysbiosis and markers of cerebral small vessel disease (cSVD), a major contributor to ADRD, is unknown. In this cross-sectional study, we examined the connection between the gut microbiome, cognitive, and neuroimaging markers of cSVD in the Framingham Heart Study (FHS). Markers of cSVD included white matter hyperintensities (WMH), peak width of skeletonized mean diffusivity (PSMD), and executive function (EF), estimated as the difference between the trail-making tests B and A. We included 972 FHS participants with MRI scans, neurocognitive measures, and stool samples and quantified the gut microbiota composition using 16S rRNA sequencing. We used multivariable association and differential abundance analyses adjusting for age, sex, BMI, and education level to estimate the association between gut microbiota and WMH, PSMD, and EF measures. Our results suggest an increased abundance of Pseudobutyrivibrio and Ruminococcus genera was associated with lower WMH and PSMD (p values < 0.001), as well as better executive function (p values < 0.01). In addition, in both differential and multivariable analyses, we found that the gram-negative bacterium Barnesiella intestinihominis was strongly associated with markers indicating a higher cSVD burden. Finally, functional analyses using PICRUSt implicated various KEGG pathways, including microbial quorum sensing, AMP/GMP-activated protein kinase, phenylpyruvate, and β-hydroxybutyrate production previously associated with cognitive performance and dementia. Our study provides important insights into the association between the gut microbiome and cSVD, but further studies are needed to replicate the findings.

Indexed as

Cerebral Small Vessel DiseasesDysbiosisAMP-Activated Protein KinasesBacteriaBacteroidetesCross-Sectional StudiesHumansRNA, Ribosomal, 16SAMP-Activated Protein KinasesRNA, Ribosomal, 16S

Identifiers

PMID37604954
PMCPMC10442369
OpenAlexW4386026343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.